May v. United States

CourtCourt of Appeals for the Federal Circuit
DecidedJune 6, 2023
Docket23-1124
StatusUnpublished

This text of May v. United States (May v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
May v. United States, (Fed. Cir. 2023).

Opinion

Case: 23-1124 Document: 38 Page: 1 Filed: 06/06/2023

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

SAMUEL J. MAY, DBA SOFT PLANET SYNERGY, LLC, Plaintiff-Appellant

v.

UNITED STATES, Defendant-Appellee ______________________

2023-1124 ______________________

Appeal from the United States Court of Federal Claims in No. 1:21-cv-01496-CNL, Judge Carolyn N. Lerner. ______________________

Decided: June 6, 2023 ______________________

SAMUEL J. MAY, Lehi, UT, pro se.

KRISTIN ELAINE OLSON, Commercial Litigation Branch, Civil Division, United States Department of Justice, Wash- ington, DC, for defendant-appellee. Also represented by BRIAN M. BOYNTON, PATRICIA M. MCCARTHY, DOUGLAS K. MICKLE. ______________________

Before REYNA, TARANTO, and STOLL, Circuit Judges. Case: 23-1124 Document: 38 Page: 2 Filed: 06/06/2023

PER CURIAM. Samuel May brought the present action against the United States in the U.S. Court of Federal Claims (Claims Court) in June 2021. Central to this action is Mr. May’s allegation that his unsuccessful 2010 lawsuit in federal dis- trict court against his former employer Amgen, Inc.— which Mr. May brought on behalf of the United States un- der the False Claims Act—alerted the United States to al- leged misconduct by Amgen and thereby helped the United States secure a settlement with Amgen in December 2012, under which Amgen paid the government more than half a billion dollars. In the present action, Mr. May seeks a share of the settlement amount, asserting constitutional, contract, tort, and 42 U.S.C. § 1983 claims against the United States. The Claims Court dismissed the action for lack of subject-matter jurisdiction. We affirm, concluding that Mr. May’s takings and contract claims are time-barred by 28 U.S.C. § 2501 and that his remaining claims are out- side the Claims Court’s jurisdiction for substantive reasons to the extent that they are not time-barred. I A Mr. May was employed from April 2002 until June 2006 by Amgen, which is not a party to this appeal or to the underlying Claims Court case. After suing Amgen in California state court for wrongful termination, among other things, see Complaint, May v. Amgen, No. SC050255 (Cal. Super. Ct. Apr. 26, 2007), Mr. May voluntarily dis- missed that suit and demanded arbitration for materially the same claims in February 2008. The arbitrator ruled in favor of Amgen in October 2011, and a Colorado state court confirmed the arbitration award in March 2012. The federal district court likewise denied Mr. May’s petition to vacate or modify the arbitration award under the Federal Arbitration Act, 9 U.S.C. §§ 1–16. Case: 23-1124 Document: 38 Page: 3 Filed: 06/06/2023

MAY v. US 3

See May v. Amgen, Inc., No. C 12-01367, 2012 WL 2196151 (N.D. Cal. June 14, 2012). The Ninth Circuit affirmed the district court’s judgment, see May v. Amgen, Inc., 564 F. App’x 313 (9th Cir. 2014) (per curiam), and the Supreme Court denied certiorari, see May v. Amgen, Inc., 574 U.S. 1193 (2015). While the arbitration was pending, on June 11, 2010, Mr. May filed a qui tam complaint against Amgen in the U.S. District Court for the Northern District of California under under the False Claims Act, 31 U.S.C. §§ 3729–3733. He alleged that Amgen, among other things, knowingly made false statements to the Food and Drug Administra- tion (FDA) and knowingly promoted a drug (Aranesp) for indications not approved by the FDA. See Complaint ¶ 10, United States ex rel. May v. Amgen Inc., No. C10-2577 (N.D. Cal. June 11, 2010). The False Claims Act imposes civil liability on “any person who,” among other things, “knowingly presents, or causes to be presented,” to the United States “a false or fraudulent claim for payment or approval.” 31 U.S.C. § 3729(a)(1)(A). An action under the False Claims Act—in district court, see 31 U.S.C. § 3732(a)—“may be commenced in one of two ways.” Vermont Agency of Natural Resources v. United States ex rel. Stevens, 529 U.S. 765, 769 (2000). The Attorney General may bring a civil action directly against the alleged false claimant, or a private person (called the relator) may bring a qui tam civil action against the alleged false claimant “in the name of the [g]overn- ment.” 31 U.S.C. § 3730(a), (b)(1). If a relator brings a qui tam action, the relator must serve a copy of the complaint and any supporting evidence on the United States, which then has 60 days to decide whether it will intervene in the action. Id. § 3730(b)(2), (4). If the United States intervenes, then it has “the primary responsibility for prosecuting the action,” but the relator may continue to participate as a party. Id. § 3730(c)(1). If Case: 23-1124 Document: 38 Page: 4 Filed: 06/06/2023

the United States declines to intervene, then the relator conducts the action, unless the court permits the United States to intervene later for good cause shown. Id. § 3730(b)(4)(B), (c)(3). The relator receives a portion of any proceeds from the qui tam action: 15–25% if the United States intervenes and 25–30% if the United States does not intervene. Id. § 3730(d)(1)–(2). See generally Vermont Agency of Natural Resources, 529 U.S. at 768–70. In Mr. May’s qui tam action, the United States elected not to intervene. Eventually, on January 5, 2012, the Northern District of California dismissed Mr. May’s qui tam suit for failure to prosecute, reasoning that Mr. May was proceeding pro se and, in the Ninth Circuit, a pro se plaintiff cannot maintain a qui tam action. See Order, United States ex rel. May v. Amgen Inc., No. C10-2577 (N.D. Cal. Jan. 5, 2012) (citing Stoner v. Santa Clara County Office of Education, 502 F.3d 1116, 1126–27 (9th Cir. 2007)). B In December 2012, Amgen settled 10 separate qui tam actions brought by relators other than Mr. May. The set- tlement agreement memorialized the United States’ con- tentions that “Amgen knowingly promoted the sale and use of Aranesp for indications,” “dosing, intervals, amounts, or regiments” that were “not approved by the [FDA].” U.S. Supp. Appx. 339 ¶ G(1)(a). The settlement agreement re- quired Amgen to pay about $587.3 million to the United States and $24.9 million to certain States (with more to be paid under a criminal plea agreement). Mr. May, believing that he was entitled to a share of the settlement, moved in April 2016 to reopen his qui tam action in the Northern District of California. See Plaintiffs’ Notice of Motion, United States ex rel. May v. Amgen Inc., No. C10-2577 (N.D. Cal. Apr. 28, 2016). The court denied the motion because Mr. May still had not retained counsel. See Order, United States ex rel. May v. Amgen Inc., No. Case: 23-1124 Document: 38 Page: 5 Filed: 06/06/2023

MAY v. US 5

C10-2577 (N.D. Cal. July 12, 2016) (citing Stoner, 502 F.3d at 1126). Mr. May appealed to the Ninth Circuit, which told him that it would dismiss the appeal unless he ob- tained counsel within 35 days. See Order, United States ex rel. May v. Amgen Inc., No. 16-16394 (9th Cir. Aug. 31, 2016) (per curiam).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell v. Hood
327 U.S. 678 (Supreme Court, 1946)
Weinberger v. Wiesenfeld
420 U.S. 636 (Supreme Court, 1975)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Keene Corp. v. United States
508 U.S. 200 (Supreme Court, 1993)
Franconia Associates v. United States
536 U.S. 129 (Supreme Court, 2002)
United States v. Navajo Nation
556 U.S. 287 (Supreme Court, 2009)
Tamerlane, Ltd. v. United States
550 F.3d 1135 (Federal Circuit, 2008)
Young v. United States
529 F.3d 1380 (Federal Circuit, 2008)
Wells v. United States
420 F.3d 1343 (Federal Circuit, 2005)
The United States v. Patrick J. Connolly
716 F.2d 882 (Federal Circuit, 1983)
Roland A. Leblanc v. United States
50 F.3d 1025 (Federal Circuit, 1995)
Gary W. Bowen v. United States
292 F.3d 1383 (Federal Circuit, 2002)
United States v. Bormes
133 S. Ct. 12 (Supreme Court, 2012)
Brandt v. United States
710 F.3d 1369 (Federal Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
May v. United States, Counsel Stack Legal Research, https://law.counselstack.com/opinion/may-v-united-states-cafc-2023.